Literature DB >> 2462015

Antiviral activity of tumour necrosis factor. Synergism with interferons and induction of oligo-2',5'-adenylate synthetase.

J Mestan1, M Brockhaus, H Kirchner, H Jacobsen.   

Abstract

Tumour necrosis factor (TNF) induces antiviral activity in HEp-2 cells. Virus yield reduction assays with vesicular stomatitis virus as challenging virus demonstrated that the antiviral state was more pronounced in confluent cultures under low serum conditions. A significant enhancement of the antiviral state was obtained by combining TNF with low concentrations of either interferon (IFN)-beta 1 or IFN-gamma. The reduction in virus yield was significantly higher than that expected from summation of the independent antiviral activities of either substance alone, i.e. TNF and IFN acted synergistically as antiviral agents. Synergism of TNF with IFN-beta or IFN-gamma appeared to be mediated by different pathways, since different requirements for pretreatment and different effects on oligo-2',5'-adenylate synthetase (2-5AS) induction were observed. Induction of 2-5AS by TNF could be shown to be an indirect event that was sensitive to an antiserum against natural IFN-beta 1.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2462015     DOI: 10.1099/0022-1317-69-12-3113

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  30 in total

1.  Tumour necrosis factor triggers granulocytes to internalize complement-coated virus particles.

Authors:  J A van Strijp; M E van der Tol; L A Miltenburg; K P van Kessel; J Verhoef
Journal:  Immunology       Date:  1991-05       Impact factor: 7.397

2.  Antiviral and immunoregulatory activities of IFN-gamma depend on constitutively expressed IL-1alpha.

Authors:  Vladimir Hurgin; Daniela Novick; Ariel Werman; Charles A Dinarello; Menachem Rubinstein
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-08       Impact factor: 11.205

3.  Blockade of virus infection by human CD4+ T cells via a cytokine relay network.

Authors:  Ann M Davis; Kristan A Hagan; Loderick A Matthews; Gagan Bajwa; Michelle A Gill; Michael Gale; J David Farrar
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

4.  An essential role for the interferon-inducible, double-stranded RNA-activated protein kinase PKR in the tumor necrosis factor-induced apoptosis in U937 cells.

Authors:  M C Yeung; J Liu; A S Lau
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

5.  Beta interferon subtype 1 induction by tumor necrosis factor.

Authors:  H Jacobsen; J Mestan; S Mittnacht; C W Dieffenbach
Journal:  Mol Cell Biol       Date:  1989-07       Impact factor: 4.272

6.  Influenza A virus replication is inhibited by tumor necrosis factor-alpha in vitro.

Authors:  H Van Campen
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

7.  Respiratory syncytial virus induces interleukin-10 by human alveolar macrophages. Suppression of early cytokine production and implications for incomplete immunity.

Authors:  J R Panuska; R Merolla; N A Rebert; S P Hoffmann; P Tsivitse; N M Cirino; R H Silverman; J A Rankin
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

8.  The role of human adenovirus early region 3 proteins (gp19K, 10.4K, 14.5K, and 14.7K) in a murine pneumonia model.

Authors:  T E Sparer; R A Tripp; D L Dillehay; T W Hermiston; W S Wold; L R Gooding
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

9.  Inflammatory infiltration of the trigeminal ganglion after herpes simplex virus type 1 corneal infection.

Authors:  T Liu; Q Tang; R L Hendricks
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

10.  The RNA binding domain of influenza A virus NS1 protein affects secretion of tumor necrosis factor alpha, interleukin-6, and interferon in primary murine tracheal epithelial cells.

Authors:  Celeste M Newby; Leah Sabin; Andrew Pekosz
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.